[Federal Register Volume 88, Number 37 (Friday, February 24, 2023)]
[Notices]
[Pages 11902-11903]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-03808]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

[Docket No.: PTO-P-2022-0037]


Joint USPTO-FDA Collaboration Initiatives; Notice of Public 
Listening Session and Request for Comments

AGENCY: United States Patent and Trademark Office, Department of 
Commerce.

ACTION: Request for comments; extension of written comment period.

-----------------------------------------------------------------------

SUMMARY: The United States Patent and Trademark Office (USPTO), 
Department of Commerce, in collaboration with the United States Food 
and Drug Administration (FDA), Department of Health and Human Services, 
is extending the written comment period for the notice titled ``Joint 
USPTO-FDA Collaboration Initiatives; Notice of Public Listening Session 
and Request for Comments'' that was published in the Federal Register 
on November 7, 2022, until March 10, 2023.

DATES: The comment period for the notice published at 87 FR 67019 is 
extended. Comments are due by March 10, 2023.

ADDRESSES: For reasons of Government efficiency, comments must be 
submitted through the Federal eRulemaking Portal at 
www.regulations.gov. This docket closed on February 6, 2023, but is now 
reopened to accept additional comments. To submit comments via the 
portal, enter docket number PTO-P-2022-0037 on the homepage and click 
``Search.'' The site will provide a search results page listing all 
documents associated with this docket. Find a reference to this 
document and click on the ``Comment'' icon, complete the required 
fields, and enter or attach your comments. Attachments to electronic 
comments will be accepted as various file types, including 
Adobe[supreg] portable document format (PDF) and Microsoft Word[supreg] 
format. Because comments will be made available for public inspection, 
information the submitter does not desire to make public, such as an

[[Page 11903]]

address or phone number, should not be included in the comments.
    Visit the Federal eRulemaking Portal for additional instructions on 
providing comments via the portal. If electronic submission of comments 
is not feasible due to a lack of access to a computer and/or the 
internet, please contact the USPTO using the contact information below 
(at FOR FURTHER INFORMATION CONTACT) for special instructions.

FOR FURTHER INFORMATION CONTACT: Linda Horner, Administrative Patent 
Judge, at 571-272-9797 or [email protected].

SUPPLEMENTARY INFORMATION: On November 7, 2022, the USPTO, in 
collaboration with the FDA, published a notice titled ``Joint USPTO-FDA 
Collaboration Initiatives; Notice of Public Listening Session and 
Request for Comments'' to seek public comments on proposed initiatives 
for collaboration between the agencies to advance President Biden's 
Executive Order on ``Promoting Competition in the American Economy'' 
and to support the provision of greater access to medicines for 
American families. See 87 FR 67019. The USPTO is extending the written 
comment period until March 10, 2023, to ensure that all stakeholders 
have a sufficient opportunity to submit comments on the questions 
presented in the November 7, 2022, notice.
    Comments previously submitted to the docket through the Federal 
eRulemaking Portal do not need to be resubmitted. Any comments sent 
directly to the USPTO after the close of the previous deadline of 
February 6, 2023, must be submitted through the Federal eRulemaking 
Portal before the newly extended deadline to be given full 
consideration. All other information and instructions to commenters 
provided in the November 7, 2022, notice remain unchanged.

Katherine K. Vidal,
Under Secretary of Commerce for Intellectual Property and Director of 
the United States Patent and Trademark Office.
[FR Doc. 2023-03808 Filed 2-23-23; 8:45 am]
BILLING CODE 3510-16-P